2025 - Hemostemix

Mar 17 / 2025

Hemostemix’s Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial

Mar 06 / 2025

Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA™) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

Mar 05 / 2025

Hemostemix Sells its 23rd ACP-01 Therapy Convertible Debenture

Feb 19 / 2025

Hemostemix Licenses CytoImmune’s BioReactor Technologies 

Feb 11 / 2025

Hemostemix PR Inc. Congratulates Luis Muñoz Marín International Airport on Achieving CEIV Pharma Certification

Feb 10 / 2025

Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors

Feb 03 / 2025

HEMOSTEMIX EXPANDS TO THE DOMINICAN REPUBLIC

Jan 29 / 2025

Hemostemix Announces First Sales Orders for ACP-01

Jan 27 / 2025

Hemostemix Up-lists to TradeGateExchange in Germany

Jan 20 / 2025

Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact

Jan 13 / 2025

Hemostemix Settlement via Depository Trust Company Plus OTCQB Update

Jan 09 / 2025

Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up

Jan 06 / 2025

Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% reimbursement of R&D expenses in cash

Jan 02 / 2025

Hemostemix is up-listing in the USA to generate liquidity

News & Media